Michael Yee, RBC analyst, shares his views on the biotech breakout. The "Fast Money" traders weigh in.
Jim Cramer highlights one group that was a clear winner of the first half of 2016.
Sam Isaly, OrbiMed Advisors founder, discusses health care industry stock picks.
As the first quarter comes to a close, one sector notably stands out in the negative column: biotech.
RBC Capital Markets BioTech Analyst Michael Yee and CastleArk Management President & CIO Jerry Castellini discuss the bull and bear cases for biotech stocks.
"Power Lunch" hosts Melissa Lee and Brian Sullivan look at stocks with analyst recommendations, including Vertex Pharmaceuticals, GoPro and Tesla.
Brian Abrahams of Jefferies, who has one of the best track records on Wall Street, just upgraded a biotech stock.
RBC Capital Markets analyst Michael Yee says there are three biotech stocks to own next year no matter how the sector performs in 2016.
Personalized medicine is more costly than traditional treatment, which worries insurers. But these drugs can improve outcomes for patients.
Jim Cramer provides his opinion on caller favorite stocks, including this telecommunications play.
Some of the names on the move ahead of the open.
Take a look at some of Wednesday's after-hours buzz: GPRO, PYPL, BWLD, YELP & more.
U.S. stock index futures pointed to a higher open on Wednesday ahead of a statement from the Fed this afternoon and more earnings.
Expectations are low that the Fed will provide any new policy insight next week, and focus should stay on economic reports and a flood of earnings.
Morgan Stanley analyzed the drug pricing issue and found which companies are the best and worst positioned in a note sent to clients on Thursday.
As investors grapple with whether or not to buy the dip, one technician has found a group of stocks that is impervious to the market’s wild swings.
A female libido drug Addyi has been approval. Does that mean feminine versions of those classic Viagra ads? Probably not. Here's why.
Check out the companies making headlines after the bell Wednesday: Skechers, Whole Foods, LifeLock & more.
The FDA approved the use of Vertex Pharmaceuticals' Orkambi, a drug aimed to treat patients with cystic fibrosis.
U.S. stocks ended little changed as investors eyed the jobs report and were on edge ahead of Greece's Sunday referendum.